Ipamorelin

Ipamorelin 5mg

Ipamorelin 5 mg is a research pentapeptide supplied as a lyophilised powder. The stated sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH₂, formula C₃₈H₄₉N₉O₅, CAS 170851-70-4, molar mass about 711.85 g/mol. In studies of the compound it acts at the ghrelin receptor, GHS-R1a. Published experiments describe its selectivity compared with earlier secretagogues, under those conditions. Those findings do not apply to this vial, and they are not a dosing guide. For laboratory research only. Not for human or veterinary administration.

Ipamorelin: A Selective Growth Hormone Secretagogue

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, GHS-R1a. It has been investigated for stimulating growth hormone release from pituitary cells.

Published experiments describe its selectivity compared with earlier secretagogues, including differences in ACTH and cortisol responses under the conditions studied. These findings should not be interpreted as proof that other hormonal effects are absent in every setting.

The supplied peptide is intended for in-vitro research only, not for human or animal administration, food, treatment or diagnostics.

Mechanism of Action of Ipamorelin

Ipamorelin interacts with the ghrelin receptor to initiate pathways associated with GH secretion. Researchers can examine receptor activity, downstream signal responses and how these change with concentration or exposure time.

A peptide experiment should include suitable controls and clearly defined measurements. Differences between cell systems, assay conditions and preparation methods can influence the observed response. Results from one model should therefore not be assumed to apply directly to another.

Research Areas and Experimental Design

Ipamorelin can be investigated in laboratory research examining endocrine signalling and secretagogue activity. Comparative experiments may assess the peptide alone or alongside a GHRH analogue, provided the study is designed to distinguish individual and combined effects.

The inclusion of Ipamorelin in a combination does not itself establish synergy. Appropriate controls help determine whether a measured signal differs from the response to either component separately.

For each research peptide, document identity, preparation conditions and concentration. These details support interpretation and reproducibility more reliably than broad claims about experimental performance.

Quality and Analytical Documentation

Review the certificate of analysis for every batch of Ipamorelin received. HPLC results provide information about purity, while appropriate identity testing helps establish whether the supplied material matches its description.

If third-party testing is advertised, request the corresponding report. A high HPLC purity percentage alone does not establish peptide content, sterility or suitability for a particular assay. Resolve any differences between the advertised specification and analytical records before beginning work.

Storage and Reconstitution

Storage

Keep Ipamorelin sealed and protected from light and moisture. Follow the product label for temperature requirements; use -20°C only where the supplier specifies frozen storage.

If instructed, allow the sealed vial to reach room temperature before opening to limit condensation. Documented storage conditions help preserve peptide stability, but the stability of a prepared solution must be assessed separately.

Reconstitution

Before you reconstitute Ipamorelin, confirm the solvent and target concentration required by your validated protocol. Bacteriostatic water should be used only where its preservative is compatible with the assay.

Follow the documented reconstitution procedure rather than assuming a universal dilution volume or shelf life. If the protocol calls for an aliquot of prepared stock, label it with its contents, concentration and preparation date.

Related Studies:

• Selective growth-hormone secretion
• Longitudinal bone growth in rats
• Postoperative ileus in bowel-resection patients